Skip to main content

Author: Nicky Saputo

“Re-branding” a disease: From NAFLD to MAFLD

Researchers believe that a re-classification of NAFLD, which affects nearly a billion people globally with no drug treatment currently on the market, is essential to improve patient understanding and industry funding to better mitigate its impact.

Continue reading

FRI sponsors NASH summit

Our teams joined virtually to hear the latest insights from regulators including the FDA, thought-leading scientists and translational and biomarker experts in drug development.

Continue reading

What is NASH?

NASH is characterized by fat accumulation and inflammation in the liver, which can lead to scarring and long-term damage.

Continue reading